Diakonos Oncology
Houston, Texas, United States · Biotechnology, Health Care, Medical
Diakonos Oncology Corp. is a clinical stage immuno-oncology company based in Houston, TX. The company is at the forefront of developing dendritic cell vaccines that leverage a patient's immune system to target and eliminate cancer cells, mimicking the body's natural response to viral infections.
Key facts
- Headquarters
- Houston, Texas, United States
- Employees
- 17
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- www.diakonosoncology.com
- Company page
Recent activity at Diakonos Oncology
- : Diakonos Oncology Appoints Donna Rill as Chief Technology Officer
- : Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer
- : Diakonos Oncology raised $11.4M in a seed round led by Restem Group Inc. to advance its dendritic cell vaccine into a Phase 2 clinical trial.
- : Diakonos Oncology Appoints Biotech Veteran Anthony Baldor as Chief Financial Officer
- : Diakonos Oncology Names Ian H. Bellayr, Ph.D. Chief Regulatory Officer
Diakonos Oncology funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2024 | Seed | $11.4M |
Leadership
- Donna Rill, Chief Technology Officer
- Laura Aguilar, Chief Medical Officer
- Anthony Baldor, Chief Financial Officer
- Ian H. Bellayr, Chief Regulatory Officer
Verified email and direct lines for Diakonos Oncology’s decision-makers are on Fundz. See plans
Employee benefit plans
Diakonos Oncology files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Diakonos Oncology in the news
- Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase - PR Newswire (Dec 15, 2025)
- Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and AAN 2026 - PR Newswire (Mar 18, 2026)
- Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study - PR Newswire (Feb 17, 2026)
- Diakonos Oncology Awarded Fast Track Designation by FDA for DOC1021 (dubodencel) in Unresectable or Metastatic Cutaneous Melanoma - PR Newswire (May 06, 2026)
- Diakonos Oncology Shares Updated DOC1021 GBM Survival Data and Unveils Melanoma Clinical Study at ASCO 2026 - PR Newswire (Jun 05, 2026)
- Diakonos Oncology Awarded Multi-Million-Dollar Research Grant by the Cancer Prevention and Research Institute of Texas to Advance DOC1021 in Refractory Melanoma - PR Newswire (Dec 10, 2025)
- Diakonos Oncology Presents Promising Preliminary Data from Phase 1 Study of DOC1021 Cell-Based Immunotherapy in Pancreatic Cancer at Society for Immunotherapy of Cancer 40th Annual Meeting - PR Newswire (Nov 07, 2025)
- Diakonos Oncology Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating DOC1021 (dubodencel) for Glioblastoma - PR Newswire (Jul 22, 2025)
Companies similar to Diakonos Oncology
- Racura Oncology · Biotechnology, Health Care, Medical, Therapeutics
- First Ascent Biomedical · Biotechnology, Health Care, Medical, Therapeutics
- Medical Technology Enterprise Consortium (MTEC) · Biotechnology, Health Care, Medical, Therapeutics
- Galecto · Biotechnology, Health Care, Medical, Therapeutics
- Actinogen Medical · Biotechnology, Health Care, Medical, Therapeutics
About Diakonos Oncology: questions and answers
What does Diakonos Oncology do?
Diakonos Oncology Corp. is a clinical stage immuno-oncology company based in Houston, TX. The company is at the forefront of developing dendritic cell vaccines that leverage a patient's immune system to target and eliminate cancer cells, mimicking the body's natural response to viral infections.
Where is Diakonos Oncology headquartered?
Diakonos Oncology is headquartered in Houston, Texas, United States.
How many employees does Diakonos Oncology have?
Diakonos Oncology has about 17 employees.
Has Diakonos Oncology raised funding?
Yes. Fundz has recorded 1 funding event for Diakonos Oncology. The most recent, Seed of $11.4M, was in Aug 2024.
What is the latest news on Diakonos Oncology?
On Aug 12, 2025, Diakonos Oncology Appoints Donna Rill as Chief Technology Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy